Core Viewpoint - TruBridge (TBRG) reported quarterly earnings of $0.79 per share, significantly exceeding the Zacks Consensus Estimate of $0.41 per share, and showing a substantial increase from $0.05 per share a year ago, representing an earnings surprise of +92.68% [1] Group 1: Earnings Performance - The company has surpassed consensus EPS estimates three times over the last four quarters [2] - The earnings for the last quarter were $0.79 per share, compared to an expected $0.4 per share, and the previous quarter's actual earnings were $0.88 per share, leading to a surprise of +120% [1][2] - The current consensus EPS estimate for the upcoming quarter is $0.39, with an expected revenue of $90.95 million, and for the current fiscal year, the estimate is $1.56 on revenues of $361.47 million [7] Group 2: Revenue Performance - TruBridge reported revenues of $87.19 million for the quarter ended December 2025, slightly missing the Zacks Consensus Estimate by 0.5%, and down from $87.36 million year-over-year [2] - The company has topped consensus revenue estimates two times over the last four quarters [2] Group 3: Stock Performance and Outlook - TruBridge shares have declined approximately 36.6% since the beginning of the year, compared to a 7.3% decline in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] - The outlook for the industry, particularly the Medical Info Systems sector, is favorable, ranking in the top 34% of over 250 Zacks industries, suggesting potential for outperformance [8]

Core Viewpoint - Hims & Hers Health, Inc. is experiencing significant stock movement, with a recent decline in share price despite a notable increase over the past month, and upcoming financial results are anticipated to show a substantial decrease in earnings per share while revenue is expected to rise. Financial Performance - The company's earnings per share (EPS) for the upcoming release are projected to be $0.02, reflecting a 90% decrease from the same quarter last year [2] - Revenue is expected to be $621.4 million, showing a 6.04% increase compared to the year-ago quarter [2] - For the entire fiscal year, earnings are projected at $0.48 per share, representing a -9.43% change from the prior year, while revenue is expected to be $2.86 billion, indicating a +21.88% change [3] Analyst Estimates - Recent modifications to analyst estimates for Hims & Hers Health, Inc. reflect evolving short-term business trends, with positive revisions indicating optimism about the business outlook [4] - The Zacks Consensus EPS estimate has moved 8.44% lower over the past month, and the company currently holds a Zacks Rank of 3 (Hold) [6] Valuation Metrics - Hims & Hers Health, Inc. has a Forward P/E ratio of 40.62, which is significantly higher than the industry average of 19.63, suggesting the company is trading at a premium [7] - The company has a PEG ratio of 2.34, compared to the industry average PEG ratio of 1.11, indicating a higher valuation relative to projected earnings growth [8] Industry Context - The Medical Info Systems industry, to which Hims & Hers belongs, has a Zacks Industry Rank of 92, placing it in the top 38% of over 250 industries [8] - The Zacks Industry Rank measures the strength of individual industry groups, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [9]

Core Viewpoint - Hims & Hers Health, Inc. has shown a significant increase in share price, outperforming the S&P 500, but there are concerns about whether this positive trend will continue leading up to the next earnings release [1] Financial Performance - The company reported earnings per share of 7 cents for Q4 2025, exceeding the Zacks Consensus Estimate of 2 cents, but down 36.3% from 11 cents in the same quarter last year [2] - Q4 revenues reached $617.8 million, reflecting a year-over-year increase of 28.4%, although this figure was 0.2% below the Zacks Consensus Estimate [3] - U.S. revenues improved by 16.8% year over year to $554.1 million, while revenues from the Rest of the World surged to $63.7 million from $6.9 million a year ago [4] - Online revenues accounted for $609.1 million, marking a 29.4% increase year over year [5] - The total number of subscribers reached 2.5 million, up 12.7% year over year, with monthly online revenue per average subscriber increasing by 10.7% to $83 [6] Margin Analysis - Gross profit for Q4 increased by 20.3% year over year to $444.4 million, but the gross margin contracted by 487 basis points to 71.9% [8] - Operating profit fell to $9.2 million, a decline of 50.6% from the previous year, with the operating margin contracting by 238 basis points to 1.5% [10] Expenses - Marketing expenses rose by 7.7% year over year to $238 million, while technology and development expenses surged by 72.5% to $40.9 million [9] Financial Position - At the end of 2025, the company had cash and cash equivalents of $577.5 million, up from $300.3 million at the end of 2024 [11] - Cumulative net cash from operating activities was $300 million, compared to $251.1 million a year ago [11] Future Outlook - For Q1 2026, the company projects revenues between $600 million and $625 million, indicating a year-over-year growth of 2%-7% [12] - For the full year 2026, revenue projections are between $2.7 billion and $2.9 billion, representing a growth of 15%-24% from 2025 levels [13] - Recent estimates have shown a downward trend, with a significant shift of -88.38% in consensus estimates [14] Industry Context - Hims & Hers Health operates within the Zacks Medical Info Systems industry, where another player, Hinge Health Inc., reported revenues of $170.73 million with no year-over-year change [17]

Company Overview - American Well Corporation (AMWL) is part of the Medical group, which consists of 924 companies and is currently ranked 9 within the Zacks Sector Rank [2] - The company belongs to the Medical Info Systems industry, which includes 42 companies and is ranked 91 in the Zacks Industry Rank [6] Performance Analysis - Year-to-date, AMWL has returned approximately 16.7%, significantly outperforming the average loss of 6.7% in the Medical group [4] - The Zacks Consensus Estimate for AMWL's full-year earnings has increased by 36.6% over the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [4] Comparative Analysis - Another outperforming stock in the Medical sector is Annexon, Inc. (ANNX), which has seen a year-to-date increase of 1.8% and has a Zacks Rank of 2 (Buy) [5] - The Medical - Biomedical and Genetics industry, to which Annexon belongs, is ranked 150 and has experienced a slight decline of -0.1% this year [7]

Company Overview - Phreesia (PHR) shares increased by 5.1% to close at $11.77, supported by higher trading volume compared to normal sessions, following a 7.4% decline over the past four weeks [1] - The company is a developer of healthcare software and is part of the Zacks Medical Info Systems industry [4] Investor Activity - Pale Fire Capital SE, a major investor, purchased 1,602,505 shares of Phreesia for approximately $18,304,680 between March 17 and 19, increasing its total holdings to 7,648,829 shares [2] Earnings Expectations - Phreesia is expected to report quarterly earnings of $0.09 per share, reflecting a year-over-year increase of 181.8%, with revenues projected at $126.37 million, up 15.2% from the same quarter last year [3] - The consensus EPS estimate for Phreesia has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Comparison - Phreesia's Zacks Rank is 3 (Hold), similar to KORU Medical Systems, Inc. (KRMD), which closed 1.2% lower at $4.3 and has returned -7.5% over the past month [4]

Core Insights - Inspire Medical Systems reported a strong fourth-quarter performance with adjusted earnings per share of $1.65, reflecting a 43.5% year-over-year increase and surpassing the Zacks Consensus Estimate by 139.1% [3] - Revenue for the fourth quarter reached $269.1 million, a 10.5% increase year-over-year, aligning with the Zacks Consensus Estimate [4] - The company has revised its revenue guidance for 2026 down to $950 million-$1 billion, indicating a growth of 4-10% from 2025 levels, while the adjusted earnings per share outlook is set between $1.85-$2.35 [8] Financial Performance - Gross profit for the fourth quarter increased by 14.4% year-over-year to $233 million, with gross margin expanding by 160 basis points to 86.6% [5] - Operating profit decreased by 44.6% year-over-year to $46.1 million, although the operating margin improved by nearly 380 basis points to 17.1% [6] - As of the end of the fourth quarter, the company had cash and cash equivalents of $404.6 million, up from $322.6 million at the end of the third quarter [7] Market Position and Outlook - The consensus estimates for Inspire Medical have shown a downward trend, with a significant shift of -5200% noted [10] - The company holds a Zacks Rank of 3 (Hold), suggesting an expectation of an in-line return in the coming months [12] - In comparison, Hinge Health Inc., a competitor in the same industry, reported stable revenues and a Zacks Rank of 2 (Buy), indicating a more favorable outlook [13][14]

Core Viewpoint - Health Catalyst (HCAT) reported quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share, but showing an improvement from $0.04 per share a year ago [1] Financial Performance - The earnings surprise for the quarter was -14.26%, with the company previously expected to post earnings of $0.05 per share but actually reporting $0.06, resulting in a +20% surprise [2] - Health Catalyst generated revenues of $74.68 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 1.45%, although this is a decline from $79.61 million in the same quarter last year [3] Stock Performance - Health Catalyst shares have declined approximately 22.2% since the beginning of the year, contrasting with a 1% decline in the S&P 500 [4] - The company's current Zacks Rank is 2 (Buy), indicating expectations for the stock to outperform the market in the near future [7] Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $73.37 million, and for the current fiscal year, it is $0.30 on revenues of $300.34 million [8] - The Medical Info Systems industry, to which Health Catalyst belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [9]

分组1 - KORU Medical Systems, Inc. reported a quarterly loss of $0.01 per share, better than the Zacks Consensus Estimate of a loss of $0.02, representing an earnings surprise of +50.00% [1] - The company posted revenues of $10.9 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.05% and showing an increase from $8.84 million year-over-year [2] - KORU Medical Systems has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times in the same period [2] 分组2 - The stock has underperformed, losing about 22.4% since the beginning of the year, compared to a 1% decline in the S&P 500 [3] - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at -$0.01 on $11.47 million in revenues for the coming quarter and -$0.01 on $49.4 million in revenues for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical Info Systems sector is in the bottom 41% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

分组1 - CareCloud, Inc. reported quarterly earnings of $0.11 per share, matching the Zacks Consensus Estimate, but down from $0.23 per share a year ago [1] - The company posted revenues of $34.42 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 5.30%, compared to $28.24 million in the same quarter last year [2] - CareCloud has surpassed consensus revenue estimates three times over the last four quarters [2] 分组2 - The stock has declined approximately 8.9% since the beginning of the year, while the S&P 500 has only declined by 1% [3] - The current consensus EPS estimate for the upcoming quarter is $0.06 on revenues of $31.78 million, and for the current fiscal year, it is $0.42 on revenues of $130.33 million [7] - The Zacks Industry Rank for Medical Info Systems is in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Insights - Tempus AI's strategic focus for 2026 is on expanding its AI-driven precision medicine platform, scaling the diagnostics business, enhancing data and AI capabilities, and strengthening relationships with healthcare providers and pharmaceutical companies, supported by a commercial pipeline with a total contract value exceeding $1.1 billion [2] Financial Performance - In 2025, Tempus reported total revenues of $1.3 billion, an increase of 83.4% year over year, with the Diagnostics segment generating $955.4 million, reflecting 111.5% year-over-year growth, driven by strong Oncology and Hereditary testing volumes [3][8] - The Data and Applications segment also saw significant growth, generating $316.4 million in revenues, up 30.9% year over year, attributed to strong momentum in the Insights data licensing business [3] Market Position and Competitors - Tempus peers, such as Inspire Medical Systems and 10x Genomics, are expected to maintain growth momentum, with Inspire benefiting from increased adoption of sleep apnea therapy devices and 10x advancing through demand for single-cell and spatial genomics technologies [4] Stock Performance - Over the past year, Tempus shares increased by 15.7%, contrasting with a 25.2% decline in the Zacks Medical Info Systems industry, while peers like Inspire Medical Systems saw a 64.9% drop, and 10x Genomics posted a gain of 96.5% [5] Growth Initiatives - Tempus anticipates strong growth in its oncology diagnostics segment, expecting a 30% growth rate driven by the increasing adoption of genomic sequencing in cancer care, supported by a comprehensive test portfolio [6][9] - The company is also focusing on scaling the Minimal Residual Disease (MRD) testing opportunity, which has shown a 56% quarter-over-quarter volume growth, with plans for gradual commercialization and reimbursement coverage [10][11] Clinical Applications and Software Development - Beyond diagnostics, Tempus is developing clinical applications and healthcare software, including AI-powered tools like TIME and Next, aimed at enhancing patient matching and care pathway intelligence, which will create new revenue opportunities and strengthen its data ecosystem [12] Future Outlook - According to the Zacks Consensus Estimate, Tempus is expected to see a 25.4% improvement in revenues for 2026, although earnings per share are projected to remain negative but improve by 39.3% over 2025 [13]